莫西沙星治疗肝硬化并发原发性腹膜炎的疗效观察 |
| |
引用本文: | 李小安,陈鲜兰,胡建,何胜,沈才飞. 莫西沙星治疗肝硬化并发原发性腹膜炎的疗效观察[J]. 华西医学, 2009, 24(3): 641-643 |
| |
作者姓名: | 李小安 陈鲜兰 胡建 何胜 沈才飞 |
| |
作者单位: | 成都军区总医院感染科,四川成都,610083;成都军区总医院感染科,四川成都,610083;成都军区总医院感染科,四川成都,610083;成都军区总医院感染科,四川成都,610083;成都军区总医院感染科,四川成都,610083 |
| |
摘 要: | 目的:观察莫西沙星治疗肝硬化并发原发性腹膜炎的疗效。方法:98例病例随机分成治疗组(51例)和对照组(47例),治疗组使用莫西沙星注射液400mg,静滴,1次/天;对照组使用头孢哌酮/舒巴坦钠2g+左氧氟沙星注射液0.2g,静滴,2次/次,疗程7~10天。结果:治疗组总有效率为90.2%,明显高于对照组72.3%(P〈0.05),并且能较快缓解患者感染的症状和体征,不良反应发生率仅为3.9%。结论:莫西沙星是治疗肝硬化并发原发性腹膜炎安全有效的药物。
|
关 键 词: | 莫西沙星 原发性腹膜炎 肝硬化 |
The Observation on Efficacy of Moxifloxacin in Treating Primary Peritonitis in Patients with Cirrhosis |
| |
Affiliation: | LI Xiao-an, CHEN Xian-lan, HU Jian, et al.( Department of Infectious Disease, General Hospital of Chengdu Military Command, Chengdu 610083, China) |
| |
Abstract: | Objective:To evaluate the efficacy of moxifloxacin in treating primary peritonitis in patients with cirrhosis. Methods: Nitety-eight patients were randomised to either moxifloxacin group(51 cases)or control group(47 cases). The moxifloxacin group received a single intravenous infusion of moxifloxacin 400 mg, qd. The control group received intravenous infusion of cefoperazone/sulbactam, 2g bid with Levofloxacin 0.2g, bids and the course of treatment is 7-10 days. Results;The total effective rate of the moxifloxacin(90. 2%)is obviously higher than that of the control group (72.30% )(P〈0.05), and the objective sign and symptom in moxifloxacin group are alleviated more rapidly. The drugrelated adverse events of moxifloxacin is only 3.9 %. Conclusion: Moxifloxacin is safe and effective drug for treating primary peritonitis in patients with cirrhosis. |
| |
Keywords: | moxifloxacin primary peritonitis cirrhosis |
本文献已被 维普 万方数据 等数据库收录! |
|